Michael Lam
Family Medicine · Alhambra, CANPI 1528184587
Payments from drug & device makers
Across 193 payments — averaging $91.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$4K
- Gilead$3K
- Amgen$2K
- AbbVie$1K
- GSK$1K
- Amarin Pharma, Inc.$1K
- plus $5K from 20 others
What the payments were for
- Food & beverage$17,670100%
- Education$250%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 36 | $3,553 |
| Gilead | 36 | $2,594 |
| Amgen(2 entities) | 22 | $2,423 |
| AbbVie(2 entities) | 13 | $1,393 |
| GSK | 10 | $1,234 |
| Amarin Pharma, Inc. | 11 | $1,151 |
| Bayer | 14 | $932 |
| Novo Nordisk | 5 | $621 |
| Lilly USA, LLC | 11 | $544 |
| Boehringer Ingelheim | 5 | $514 |
| Merck | 8 | $330 |
| Abbott | 3 | $311 |
| Johnson & Johnson | 3 | $258 |
| Esperion Therapeutics, Inc. | 2 | $250 |
| Radius Health, Inc. | 2 | $250 |
| Vivus LLC | 2 | $245 |
| Madrigal Pharmaceuticals | 1 | $150 |
| Phathom Pharmaceuticals, Inc. | 1 | $125 |
| Mylan Specialty L.p. | 1 | $125 |
| Kowa Pharmaceuticals America, Inc. | 1 | $125 |
| Novartis | 1 | $125 |
| Lexicon Pharmaceuticals, Inc. | 1 | $115 |
| Urovant Sciences Inc | 1 | $114 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $100 |
| Dexcom, Inc. | 1 | $99 |
| Galderma Laboratories, L.p. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$17,694 in reported general payments places this provider in the 95th percentile of 10,533 family medicine providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 787 | $631,635 |
| FarxigaDapagliflozin Propanediol | 479 | $411,971 |
| JanuviaSitagliptin Phosphate | 352 | $272,395 |
| KerendiaFinerenone | 323 | $236,475 |
| JanumetSitagliptin Phos/Metformin Hcl | 276 | $220,447 |
| VascepaIcosapent Ethyl | 699 | $145,963 |
| VemlidyTenofovir Alafenamide | 47 | $65,226 |
| ProliaDenosumab | 38 | $61,803 |
| Icosapent Ethyl | 495 | $57,263 |
| DapagliflozinDapagliflozin Propanediol | 92 | $54,947 |
| Dermacinrx LidogelLidocaine Hcl | 13 | $46,613 |
| Cyclosporine | 115 | $46,418 |
| Diclofenac Sodium | 246 | $40,939 |
| LofenaDiclofenac Potassium | 16 | $31,459 |
| Omeprazole-Sodium BicarbonateOmeprazole/Sodium Bicarbonate | 14 | $30,550 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta | $514 | $645,440804 claims |
| MerckJanuvia, Janumet | $330 | $492,843628 claims |
| AstraZenecaFarxiga | $3,553 | $411,971479 claims |
| BayerKerendia | $932 | $236,475323 claims |
| GileadVemlidy | $2,594 | $65,22647 claims |
| AmgenProlia | $2,423 | $61,80338 claims |
| AbbVieRestasis | $1,393 | $29,53547 claims |
| Novo NordiskRybelsus | $621 | $12,84414 claims |
| GSKBreo Ellipta, Arexvy | $1,234 | $11,77034 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 10,533 family medicine providers in California.
Other family medicine in Alhambra
- Amina HaggagNorthridge$112.8M
- Steven ReynoldsLong Beach$53M
- Rizwana MohseniLake Forest$26.7M
- Daniel JohnsonSan Diego$15.7M
- Stacey LayleSan Diego$14.8M
- Apinya VutikullirdCypress$14.3M
- Hanid AudishSpring Valley$13.6M
- Augusto FocilOxnard$12.6M
- Jack VuLong Beach$10.1M
- Suzanne FussellOxnard$8.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.